Israeli study finds the added antibody protection from a fourth COVID-19 vaccine dose is not enough to prevent Omicron infection; Texas abortion law remains in effect after appeals court ruling; insurer spending for the unproven COVID-19 drug ivermectin was estimated at $2.5 million for a week last summer.
As reported by USA Today, findings of a preliminary study conducted at an Israeli hospital indicated that the increase in antibodies created by a fourth dose of COVID-19 vaccine was not enough to prevent infections from the Omicron variant. With more than 500,000 people having received their fourth doses in Israel, findings of the study underscore concerns around disproportionate vaccine distribution in underserved countries that have faced shortages of vaccines. Yesterday, the World Health Organization announced that its COVAX program delivered 1 billion doses of COVID-19 vaccines to poor nations worldwide; the announcement noted that the milestone is only a reminder of the work that remains.
The 5th US Circuit Court of Appeals in New Orleans ruled yesterday against sending the controversial Texas abortion law back to the only judge who has ever blocked the restrictions, which opponents fighting the case said will allow the law to remain in effect for weeks if not months. As reported by the Associated Press, the ruling indicates that legal challenges to the law will next be heard by the Texas Supreme Court, and may not come until after the US Supreme Curt makes a ruling in Mississippi’s case to overturn the landmark Roe v Wade and the 1992 Planned Parenthood v Casey decisions that increased abortion rights nationwide.
A study published last week in JAMA showed that needless insurer spending on the unproven COVID-19 treatment ivermectin in the United States was estimated at $2.5 million for the week of August 13, 2021, which would extrapolate to a total sum of $130 million annually. As reported by CIDRAP, antivaccine advocates have touted the effectiveness of ivermectin despite a lack of supporting evidence and warnings by the FDA against its use for COVID-19. For the week of August 13, private and Medicare plans paid an estimated $1,568,996 and $924,720, respectively, for ivermectin prescriptions for COVID-19.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for Health and Human Services (HHS) leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More